# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Tiago Fauth initiates coverage on WAVE Life Sciences (NASDAQ:WVE) with a Overweight rating and announces...
WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $...
Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA me...
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next pha...
Truist Securities analyst Joon Lee reiterates WAVE Life Sciences (NASDAQ:WVE) with a Buy and maintains $17 price target.
Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and raises the price target from $10 to $19.
Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-exp...